[Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial.

Walter T, Jann H, Ansquer C, Deshayes E, Garcia-Carbonero R, Teule A et al. · 2026 · Lancet · Atlas ID WALTER2026

What this study shows

Phase 3 RCT (COMPETE, Lancet 2026) found [177Lu]Lu-edotreotide (PRRT) had superior progression-free survival vs everolimus (mTOR inhibitor) in advanced somatostatin receptor-positive GEP-NETs, establishing PRRT as preferred over mTOR inhibition in this setting.

Abstract

ShowHide

Peptide receptor radionuclide and targeted therapy are both approved treatment options for patients with metastatic gastroenteropancreatic neuroendocrine tumours (GEP NETs), but clinical evidence for preferred sequencing is scarce. The COMPETE trial evaluated the efficacy and harms of peptide receptor radionuclide therapy ([Lu]Lu-edotreotide) versus targeted molecular therapy (everolimus) in patients with advanced, progressive, somatostatin receptor-positive GEP NETs.

Read the full abstract →

At a glance

Evidence type	H Human study Marked H because it is direct evidence from a human clinical trial or human cohort; the code names the kind of study, not its quality -- a small, well-run trial is still H.
Study type	2 - Human Clinical Trial
Model system	Human RCT
Journal	Lancet
Year	2026
Peer reviewed	Yes
Record last updated	2026-08-22
Source	DOI 10.1016/S0140-6736(26)00604-5

Extracted findings

Intervention	Everolimus (mTOR inhibitor) vs [177Lu]Lu-edotreotide
Target	mTORC1
Model	Human
Effect	PRRT superior to everolimus on PFS; mTOR inhibition inferior as first-line in GEP-NETs

Cite this paper

ShowHide

Walter, T., et al. (2026). [Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial. Lancet. https://doi.org/10.1016/S0140-6736(26)00604-5

@article{WALTER2026,
  author       = {Walter, T. and Jann, H. and Ansquer, C. and Deshayes, E. and Garcia-Carbonero, R. and Teule, A. and others},
  title        = {{[Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial}},
  journal      = {Lancet},
  year         = {2026},
  doi          = {10.1016/S0140-6736(26)00604-5},
}

Cite this Atlas record

The record is the Atlas's own work — the evidence label, the extracted findings and the links. It is cited as part of the dataset, not as the paper.

Barton, O. (2026). Oliver's mTOR Atlas (record WALTER2026) [Data set]. https://mtor-atlas.org/study/WALTER2026/ · Dataset DOI 10.5281/zenodo.22059963

@misc{atlas_WALTER2026,
  author       = {Barton, Oliver},
  title        = {{Oliver's mTOR Atlas}, record WALTER2026},
  howpublished = {Data set},
  year         = {2026},
  url          = {https://mtor-atlas.org/study/WALTER2026/},
  doi          = {10.5281/zenodo.22059963}
}